Cognition Therapeutics (CGTX) Cash & Current Investments (2020 - 2026)

Cognition Therapeutics (CGTX) has reported Cash & Current Investments for 7 consecutive years, with $31.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments rose 89.49% year-over-year to $31.1 million; the TTM figure through Mar 2026 stood at $31.1 million (up 89.49% YoY), while the FY2025 annual figure was $36.8 million, up 47.19% from the prior year.
• Cash & Current Investments slipped to $31.1 million in Q1 2026 per CGTX's latest filing, from $36.8 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $51.5 million in Q1 2022 and bottomed at $10.7 million in Q2 2025.
• Historically, Cash & Current Investments has averaged $33.5 million across 5 years, with a median of $34.7 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Current Investments surged 461.57% — and 2025, when it slumped 62.35%.
• Cognition Therapeutics' Cash & Current Investments stood at $41.6 million in 2022, then dropped by 28.01% to $29.9 million in 2023, then fell by 16.42% to $25.0 million in 2024, then soared by 47.19% to $36.8 million in 2025, then decreased by 15.43% to $31.1 million in 2026.
• Business Quant data shows CGTX's Cash & Current Investments at $31.1 million in Q1 2026, $36.8 million in Q4 2025, and $39.3 million in Q3 2025.